Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris

American Journal of Cardiology

Volumn 84, Issue 12, 1999, Pages 1391-1395

  Rabah, Maher M ^a   Premmereur, Jerome ^b   Graham, Mariann ^a   Fareed, Jawed ^c   Hoppensteadt, Debra A ^c   Grines, Lorelie L ^a   Grines, Cindy L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b Rhone Poulenc Rorer SA   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; GLYCERYL TRINITRATE; HEPARIN; PROTHROMBIN A;

ADULT; AGED; ANGINA PECTORIS; ANGIOGRAPHY; ARTICLE; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; ELECTIVE SURGERY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS;

AGED; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; STENTS; TREATMENT OUTCOME;

EID: 0032711331     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00582-2     Document Type: Article

References (28)

1. Hirsh J., Levine M.N. Low molecular weight heparin. Blood. 79:1992;1-17.
2. Melandri G., Semprini F., Cervi V., Candiotti N., Branzi A., Palazzini E., Magnani B. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol. 72:1993;450-454.
3. Samama M.M., Bara L., Gerotziafas G.T. Mechanisms for the antithrombotic activity in of low molecular weight heparins (LMWHs). Haemostasis. 24:1994;105-117.
4. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., Kelton J.G. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
5. Turpie A.G., Levine M.N., Hirsh J., Carter C.J., Jay R.M., Powers P.J., Andrew M., Hull R.D., Gent M. A randomized controlled trial of a low-molecular-weight heparin to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 315:1985;925-929.
6. Nurmohamed M.T., Rosendaal F.R., Buller H.R., Dekker Em Hommes D.W., Vandenbroucke J.P., Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery a meta-analysis . Lancet. 340:1992;152-156.
7. Gurfinkel E.P., Manos E.J., Mejail R.I., Cerda M.A., Duronto E.A., Garcia L.N., Daroca A.M., Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
8. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
9. Cohen M., Demers C., Gurfinkel E.P. A comparison of low- molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452.
10. Rath B., Bennett D.H. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J. 63:1990;18-21.
11. Ogilby J.D., Kopelman H.A., Klein L.W., Agarwal J.B. Adequate heparinization during PTCA assessment using activated clotting times . Cathet Cardiovasc Diagn. 18:1989;206-209.
12. Ferguson J.J., Dougherty K.G., Gaos C.M., Bush H.S., Marsh K.C., Leachman D.R. Relationship between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 23:1994;1061-1065.
13. The thrombolysis in myocardial infarctions (TIMI) trial. N Engl J Med. 3128:1985;932-936.
14. Detre K.M., Holmes D.R., Holubkow R., Cowley M.J. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 82:1990;739-750.
15. Ambrose J.A., Winters S.L., Stern A., Eng A., Teichlholz, Gorlin R., Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 5:1985;609-616.
16. Fuster V., Badimon L., Badimon J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
17. Smith A.J., Holt R.E., Fitzpatrick K., Palacios I.F., Gold H.K., Werner W., Bovill E.G., Fuster V., Jang I.K. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J. 131:1996;434-439.
18. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 327:1992;141-145.
19. Waksman R., King S. III, Douglas J., Slen Y., Wwing H., Mueller L., Ghazzal Z.M.B., Weintraub W.S. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol. 75:1995;886-889.
20. Ellis S.G., Roubin G.S., Wilentz J., Douglas J.S., King S.B. III. Effect of 18- to 24-hour heparin administration for prevention of restenosis after coronary angioplasty. Am Heart J. 117:1989;777-782.
21. Friedman H., Cragg D., Glazier S., Gangadharan V., Marsalese D.L., Schreiber T.L., O'Neill W.W. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol. 24:1994;1214-1219.
22. Dougherty K.G., Gaos C.M., Bush H.S., Leachman D.R., Ferguson J.J. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn. 26:1992;260-263.
23. Schmid K.M., Preisack M., Voelker W., Sujatta M., Karsch K.R. First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost. 19:1993;155-159.
24. Fernandez-Aviles F., Alonso J.J., Duran J.M., Gimeno F., Munoz C., de la Fuentz L., San Roman J.A. Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen. J Am Coll Cardiol. 27:1996;22-29.
25. Karsch K.R., Preisack M.B., Baildon R., Eschenfelder V., Foley D., Garcia E.J., Kaltenbach M., Meisner C., Selbmann H.K., Serruys P.W., Shiu M.F., Sujatta M., Bonan R. Low molecular weight heparin (riviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blinded, unfractionated heparin and placebo-controlled, multicentered trial (REDUCE trial) . J Am Coll Cardiol. 28:1996;1437-1443.
26. Rosenberg R.D. Heparin, antithrombin, and abnormal clotting. Annu Rev Med. 29:1978;367-378.
27. Okuno R., Crockatt D. Platelet factor 4 activity and thromboembolic episodes. Am J Clin Pathol. 67:1977;351-355.
28. Grill H.P., Spero J.E., Granato J.E. Comparison of activated partial thromboplastin time to activated clotting time for adequacy of heparin anticoagulation just before percutaneous transluminal coronary angioplasty. Am J Cardiol. 71:1993;1219-1220.